PathGroup, which is backed by Pritzker Private Capital has acquired DermLab, a Birmingham, Alabama-based dermatopathology laboratory. No financial terms were disclosed.
NASHVILLE, Tenn.— August 30, 2021 – PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of DermLab, an independent dermatopathology laboratory based in Birmingham, AL. The addition of DermLab is PathGroup’s second dermatology acquisition in 2021 and enhances the company’s dermatopathology capabilities, a key strategic initiative.
Building on previous acquisitions of Atlanta Dermatopathology and SkinDx, DermLab’s capabilities significantly extend PathGroup’s presence in dermatopathology and strengthen its position in the Southeastern United States. The combination allows existing DermLab clients to access PathGroup’s state-of-the-art molecular and clinical pathology services. Together, PathGroup and DermLab will provide physicians and patients across the Southeast with leading dermatopathology, digital pathology and clinical services.
“We are pleased to welcome DermLab’s talented pathologists to the growing PathGroup family of nearly 200 pathologists,” said Ben W. Davis, M.D., President and Chief Executive Officer of PathGroup. “As PathGroup continues to expand our dermatopathology capabilities, we will be guided by our commitment to physician leadership, diagnostic excellence and high-quality patient services.”
Founded by Charles A. Parrish, M.D., Michael K. Jacobs, M.D., and Stephen E. Mason, M.D. in 2013, DermLab will continue with its singular focus on exceptional diagnostic dermatopathology and unsurpassed customer service for its clients. “PathGroup and DermLab together will provide the highest-quality dermatopathology services to our clients and patients,” said Michael K. Jacobs, M.D., Founding Partner of DermLab. “Our organizations share the same values and we are a strong cultural fit. I am proud of our team and excited for opportunities to better serve patients and physicians within the PathGroup family.”
Founded in 1965, PathGroup is a premier provider of anatomic, clinical, molecular, and digital pathology services in the United States. Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry-standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers, and most importantly, patients. One Lab; Total Service. PathGroup is owned by Pritzker Private Capital along with management. For more information, visit pathgroup.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products, services, and health-care sectors. The firm’s differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com